Literature DB >> 20691307

Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]).

Scott J Denardo1, Franz H Messerli, Efrain Gaxiola, Juan M Aranda, Rhonda M Cooper-Dehoff, Eileen M Handberg, Yan Gong, Annette Champion, Qian Zhou, Carl J Pepine.   

Abstract

The optimal blood pressure (BP) to prevent major adverse outcomes (death, myocardial infarction, and stroke) for patients with hypertension and coronary artery disease who have undergone previous revascularization is unknown but might be influenced by the type of revascularization procedure. We analyzed data from the INternational VErapamil SR-Trandolapril STudy, focusing on the relation between BP and the outcomes of 6,166 previously revascularized patients, using the 16,410 nonrevascularized patients as a reference group. The previous revascularization strategy consisted of coronary artery bypass grafting (CABG, 45.2%), percutaneous coronary intervention (PCI, 42.1%), or both (CABG+PCI, 12.8%). Patients who had undergone both CABG+PCI and CABG-only had a greater adverse outcome risk (adjusted hazard ratio 1.27% and 1.20%, 95% confidence interval 1.06 to 1.53 and 1.07 to 1.35, respectively). The risk was similar for PCI-only patients (adjusted hazard ratio 1.04, 95% confidence interval 0.92 to 1.19). The relations between the adjusted hazard ratio and on-treatment BP appeared J-shaped for each revascularization strategy, accentuated for PCI and diastolic BP (DBP), but excepting CABG only and DBP for which the relation was linear and positive. In conclusion, major adverse outcomes were more frequent in patients with coronary artery disease who had undergone previous CABG, with or without PCI, compared to those with previous PCI only. This likely reflected more severe vascular disease. The relation to systolic BP was J-shaped for each strategy. Among those patients with previous CABG only, the linear relation with DBP suggested that more complete revascularization might attenuate hypoperfusion at a low DBP. The management of BP might, therefore, require modification of targets according to the revascularization strategy to improve outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691307      PMCID: PMC3005196          DOI: 10.1016/j.amjcard.2010.03.056

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.

Authors:  Pramod K Kuchulakanti; William W Chu; Rebecca Torguson; Patrick Ohlmann; Seung-Woon Rha; Leonardo C Clavijo; Sang-Wook Kim; Ahn Bui; Natalie Gevorkian; Zhenyi Xue; Kimberly Smith; Jana Fournadjieva; William O Suddath; Lowell F Satler; Augusto D Pichard; Kenneth M Kent; Ron Waksman
Journal:  Circulation       Date:  2006-02-20       Impact factor: 29.690

Review 2.  Propensity scores in cardiovascular research.

Authors:  Ralph B D'Agostino
Journal:  Circulation       Date:  2007-05-01       Impact factor: 29.690

3.  Enhancement of stent-induced thromboembolism by residual stenoses: contribution of hemodynamics.

Authors:  S Sukavaneshvar; G M Rosa; K A Solen
Journal:  Ann Biomed Eng       Date:  2000-02       Impact factor: 3.934

4.  Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  Michael Domanski; Gary Mitchell; Marc Pfeffer; James D Neaton; James Norman; Kenneth Svendsen; Richard Grimm; Jerome Cohen; Jeremiah Stamler
Journal:  JAMA       Date:  2002 May 22-29       Impact factor: 56.272

5.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

6.  Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy.

Authors:  Scott J Denardo; Franz H Messerli; Efrain Gaxiola; Juan M Aranda; Rhonda M Cooper-Dehoff; Eileen M Handberg; Yan Gong; Annette Champion; Qian Zhou; Carl J Pepine
Journal:  Hypertension       Date:  2009-02-23       Impact factor: 10.190

7.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

8.  Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

Authors:  C J Pepine; E Handberg-Thurmond; R G Marks; M Conlon; R Cooper-DeHoff; P Volkers; P Zellig
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

9.  A canine model of acute coronary artery stenosis: effects of deliberate hypotension.

Authors:  R F Hickey; E D Verrier; R W Baer; G J Vlahakes; G Fein; J I Hoffman
Journal:  Anesthesiology       Date:  1983-09       Impact factor: 7.892

  9 in total
  10 in total

Review 1.  The j-point phenomenon in aggressive therapy of hypertension: new insights.

Authors:  Gurusher S Panjrath; Sameer Chaudhari; Franz H Messerli
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

2.  Pulse pressure and cardiovascular risk in diseased patients.

Authors:  P Jankowski; T Weber
Journal:  J Hum Hypertens       Date:  2015-08-13       Impact factor: 3.012

3.  J Curve in Hypertension.

Authors:  Tanja Dudenbostel; Suzanne Oparil
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-06-19

Review 4.  A clinical algorithm to determine target blood pressure in the elderly: evidence and limitations from a clinical perspective.

Authors:  Jinho Shin; Kwang-Il Kim
Journal:  Clin Hypertens       Date:  2022-06-15

5.  Post-operative blood pressure and 3-year major adverse cardiac events in Chinese patients undergoing PCI.

Authors:  Lijun Gan; Dandan Sun; Yuntao Cheng; Deyang Wang; Fen Wang; Lin Wang; Wei Li; Dandan Shen; Daotong Guo; Zonglei Zhang; Haiyan Wang; Jinli Li; Yong Yang; Tao Liang
Journal:  BMC Cardiovasc Disord       Date:  2021-12-30       Impact factor: 2.298

6.  Blood pressure and mortality after percutaneous coronary intervention: a population-based cohort study.

Authors:  Chung-Woo Lee; Joo Kyung Lee; Do Hoon Kim; Joo-Hyun Park; Yeon Joo Choi; Hyunjin Kim; Kyungdo Han; Jin-Hyung Jung
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

7.  Prognostic impact of baseline low blood pressure in hypertensive patients with stable coronary artery disease of daily clinical practice.

Authors:  Martín Ruiz Ortiz; Elías Romo; Dolores Mesa; Mónica Delgado; Cristina Ogayar; Manuel Anguita; Juan C Castillo; José M Arizón; José Suárez de Lezo
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-14       Impact factor: 3.738

8.  Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy.

Authors:  Steen Neldam; Dingliang Zhu; Helmut Schumacher
Journal:  Int J Hypertens       Date:  2013-06-17       Impact factor: 2.420

9.  Blood Pressure Targets and Clinical Outcomes in Patients with Acute Myocardial Infarction.

Authors:  Hyukjin Park; Young Joon Hong; Jae Yeong Cho; Doo Sun Sim; Hyun Ju Yoon; Kye Hun Kim; Ju Han Kim; Youngkeun Ahn; Myung Ho Jeong; Jeong Gwan Cho; Jong Chun Park
Journal:  Korean Circ J       Date:  2017-07-12       Impact factor: 3.243

10.  Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.

Authors:  Magnus O Wijkman; Brian Claggett; Rafael Diaz; Hertzel C Gerstein; Lars Køber; Eldrin Lewis; Aldo P Maggioni; Emil Wolsk; David Aguilar; Rhonda Bentley-Lewis; John J McMurray; Jeffrey Probstfield; Matthew Riddle; Jean-Claude Tardif; Scott D Solomon; Marc A Pfeffer
Journal:  Cardiovasc Diabetol       Date:  2020-10-12       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.